Isolation and transplantation of highly purified autologous peripheral CD34+ progenitor cells: Purging efficacy, hematopoietic reconstitution in non-Hodgkin's lymphoma (NHL): Results of Japanese phase II study

Bone Marrow Transplantation

Volumn 35, Issue 5, 2005, Pages 479-487

  Imai, Y ^a   Chou, T ^a   Tobinai, K ^b   Tanosaki, R ^b   Morishima, Y ^c   Ogura, M ^c   Shimazaki, C ^d   Taniwaki, M ^d   Hiraoka, A ^e   Tanimoto, M ^f   Koike, T ^g   Kogawa, K ^h,m   Hirai, H ⁱ   Yoshida, T ^j   Tamura, K ^k   Kishi, K ^l   Hotta, T ^l  

^a NIIGATA CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^e OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^f OKAYAMA UNIVERSITY   (Japan)

^g HOKKAIDO UNIVERSITY   (Japan)

^h SAPPORO MEDICAL UNIVERSITY HOSPITAL   (Japan)

ⁱ UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^j TOYAMA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^k FUKUOKA UNIVERSITY   (Japan)

^l TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^m Tokeidai Hospital   (Japan)

more..

Author keywords

Autologous PBSCT; CD34+ selection; High dose chemotherapy; Magnetic activated cell sorting system; Non Hodgkin's lymphoma; Phase II study

Indexed keywords

CARBOPLATIN; CD19 ANTIGEN; CD20 ANTIGEN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN HEAVY CHAIN; RANIMUSTINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ALOPECIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW PURGING; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL ISOLATION; CELL LOSS; CELL SELECTION; CELL SORTER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTAMINATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; ENTEROCOLITIS; ETHNOLOGY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GENE REARRANGEMENT; HUMAN; HUMAN CELL; JAPAN; LIVER DISEASE; LYMPHOMA CELL; MAGNETISM; MALE; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; NEUTROPHIL; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PURIFICATION; REAL TIME POLYMERASE CHAIN REACTION; SEPTICEMIA; THROMBOCYTE; TIME; VIRUS INFECTION;

ADULT; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; CLONE CELLS; FEMALE; GENE REARRANGEMENT; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOMAGNETIC SEPARATION; IMMUNOPHENOTYPING; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM CIRCULATING CELLS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POLYMERASE CHAIN REACTION; TRANSPLANTATION, AUTOLOGOUS;

EID: 20144367074     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704819     Document Type: Article

References (24)

1. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-1545.
2. Schenkein DP, Roitman D, Miller KB et al. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 1997; 3: 210-216.
3. Haioun C, Lepage E, Gisselbrecht C et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH 87-2 protocol - A groupe d'Etude des lymphomas de l'Adulte study. J Clin Oncol 2000; 18 3025-3030.
4. Shipp MA, Abeloff MD, Antman KH et al. International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. J Clin Oncol 1999; 17: 423-429.
5. Sharp JG, Joshi SS, Armitage JO et al. Significance of detection of occult non-Hodgkin's lymphoma in histologically uninvolved bone marrow by a culture technique. Blood 1992; 79: 1074-1080.
6. Ratanatharathorn V, Uberti J, Karanes C et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patinents with non-Hodgkin's lymphoma. Blood 1994; 84: 1050-1055.
7. Miltenyi S, Muller W, Weichel W et al. High-gradient magnetic cell separation with MACS. Cytometory 1990; 11: 231-238.
8. + hematopoietic progenitor cells by high-gradient magnetic cell sorting (MACS). In: Miltenyi S, Thiel A (eds). Hematopietic Stem Cells: The Mulhouse Manual. Alphamed Press: Dayton, OH, USA, 1994, pp 201-213.
9. Chou T, Ishiguro T, Imajo K et al. A multicenter early phase II study of high-dose chemotherapy with autologous peripheral blood stem cell transplantation for treatment of intermediate grade non-Hodgkin's lymphoma. Jpn J Clin Hematol 1999; 40: 1058-1067.
10. Cheson BD, Horning SJ, Coiffier B et al. Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244-1253.
11. + cells isolated using magnetically activated cell selection provide rapid engraftment following high-dose chemotherapy in breast cancer patients. Bone Marrow Transplant 2000; 25: 243-249.
12. Shpall EJ, LeMaistre CF, Holland K et al. A prospective randomized trial of buffy coat versus CD34-selected autologous bone marrow support in high-risk breast cancer patients receiving high-dose chemotherapy. Blood 1997; 90: 4313-4320.
13. + peripheral blood stem cells: retained engraftment capability and reduced tumour cell content. Br J Haematol 1999; 104: 382-391.
14. Henon PR, Liang H, Beckwirth G et al. Comparison of hemopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. Bone Marrow Transplant 1992; 9: 285-291.
15. Roberts MM, To LB, Gillis D et al. Immune reconstitution following peripheral blood stem cell transplantation, autologous bone marrow transplantation and allogeneic bone marrow transplantation. Bone Marrow Transplant 1993; 12: 469-475.
16. Miyamoto T, Gondo H, Miyoshi Y. Early viral complications following CD34-selected autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Br J Haematol 1998; 100: 348-350.
17. Holmberg LA, Boeckh M, Hooper H et al. Increased incidence of Cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood 1999; 94: 4029-4035.
18. + enriched peripheral blood progenitor cell (PBPC) transplantation is associated with higher morbidity in patients with lymphoma when compared to unmanipulated PBPC transplantation. Bone Marrow Transplant 2000; 26: 831-836.
19. + selection systems. Stem Cells 1997; 15: 297-304.
20. Freedman AS, Neuberg D, Mauch P et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999; 94: 3325-3333.
21. Horning SJ, Negrin RS, Hoppe RT et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete remission: results of a phase II clinical trial. Blood 2001; 97: 404-409.
22. Schouten HC, Qian W, Kvaloy S et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results form the randomized European CUP trial. J Clin Oncol 2003; 21: 3918-3927.
23. Magni M, Di Nicola M, Devizzi L et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96: 864-869.
24. Flohr T, Hess G, Kolbe K et al. Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL. Bone Marrow Transplant 2002; 29: 769-775.